Showing results (221-230 of 322) with videos related to

Sort By:
Pageof 33
American Journal of Hematology|March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Future Oncology (London, England)|May 5, 2022
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study designJohn Mascarenhas, Claire N Harrison, Jean-Jacques Kiladjian, et al.
Haematologica|June 2, 2016
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialHaifa Kathrin Al-Ali, Martin Griesshammer, Philipp le Coutre, et al.
Blood|April 18, 2013
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus projectGiovanni Barosi, Ruben Mesa, Guido Finazzi, et al.
The Lancet. Haematology|June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre studyClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
American Journal of Hematology|April 23, 2014
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patientsAyalew Tefferi, Emnet A Wassie, Paola Guglielmelli, et al.
Blood Cancer Journal|March 7, 2021
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use programAlessandro Rambaldi, Alessandra Iurlo, Alessandro M Vannucchi, et al.
Scientific Reports|July 24, 2019
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutantsSimona Salati, Elena Genovese, Chiara Carretta, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
American Journal of Hematology|April 12, 2021
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive casesNaseema Gangat, Paola Guglielmelli, Natasha Szuber, et al.
Pageof 33